Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.

O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC.

Transfusion. 2007 Feb;47(2):316-25.

PMID:
17302779
2.

Nucleic acid testing for transfusion-transmissible agents.

Stramer SL.

Curr Opin Hematol. 2000 Nov;7(6):387-91. Review.

PMID:
11055512
3.

The risk of transfusion-transmitted infections in sub-Saharan Africa.

Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I.

Transfusion. 2010 Feb;50(2):433-42. doi: 10.1111/j.1537-2995.2009.002402.x. Epub 2009 Oct 15. Review.

PMID:
19843290
4.

Risk management in blood transfusion services.

Whyte G.

Vox Sang. 1998;74 Suppl 2:105-9. Review.

PMID:
9704431
5.

Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century.

Dwyre DM, Fernando LP, Holland PV.

Vox Sang. 2011 Jan;100(1):92-8. doi: 10.1111/j.1423-0410.2010.01426.x. Review.

PMID:
21175659
6.

The risks of transfusion-transmitted infection: direct estimation and mathematical modelling.

Kleinman SH, Busch MP.

Baillieres Best Pract Res Clin Haematol. 2000 Dec;13(4):631-49. Review.

PMID:
11102281
7.

Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.

Zou S, Stramer SL, Dodd RY.

Transfus Med Rev. 2012 Apr;26(2):119-28. doi: 10.1016/j.tmrv.2011.07.007. Epub 2011 Aug 25. Review.

PMID:
21871776
8.

Hepatitis B virus blood screening: unfinished agendas.

Comanor L, Holland P.

Vox Sang. 2006 Jul;91(1):1-12. Review. Erratum in: Vox Sang. 2007 Apr;92(3):278.

PMID:
16756595
9.

Nucleic acid testing (NAT) in high prevalence-low resource settings.

El Ekiaby M, Lelie N, Allain JP.

Biologicals. 2010 Jan;38(1):59-64. doi: 10.1016/j.biologicals.2009.10.015. Epub 2010 Jan 15. Review.

PMID:
20079664
10.
11.

HIV, HBV and HCV: new developments related to transfusion safety.

Busch MP.

Vox Sang. 2000;78 Suppl 2:253-6. Review. No abstract available.

PMID:
10938963
12.

Hepatitis C virus and blood transfusion: past and present risks.

van der Poel CL.

J Hepatol. 1999;31 Suppl 1:101-6. Review.

PMID:
10622570
13.

Tissue donation and virus safety: more nucleic acid amplification testing is needed.

Pruss A, Caspari G, Krüger DH, Blümel J, Nübling CM, Gürtler L, Gerlich WH.

Transpl Infect Dis. 2010 Oct;12(5):375-86. doi: 10.1111/j.1399-3062.2010.00505.x. Review.

PMID:
20412535
14.

Current viral risks of blood and blood products.

Dodd RY.

Ann Med. 2000 Oct;32(7):469-74. Review.

PMID:
11087167
15.

Genomic screening for blood-borne viruses in transfusion settings.

Allain JP.

Clin Lab Haematol. 2000 Feb;22(1):1-10. Review.

PMID:
10762297
16.

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection.

Kleinman S, Busch MP, Korelitz JJ, Schreiber GB.

Transfus Med Rev. 1997 Jul;11(3):155-72. Review. No abstract available.

PMID:
9243769
17.

Screening of HIV infection: role of molecular and immunological assays.

Weber B.

Expert Rev Mol Diagn. 2006 May;6(3):399-411. Review.

PMID:
16706742
18.
19.

The disappearance of transfusion-transmitted hepatitis C virus infections in the United States.

Gresens CJ, Holland PV.

Clin Liver Dis. 2001 Nov;5(4):1105-13. Review.

PMID:
11685798
20.

Epidemiology of viral infections in the Swedish blood-donor population.

Lindholm A.

Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 3:S13-7; discussion S19. Review.

PMID:
7749044

Supplemental Content

Support Center